NCT00004929View on ClinicalTrials.gov

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

MUC-2-KLH vaccine

BIOLOGICAL

QS21

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00004929 - Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer | Biotech Hunter | Biotech Hunter